Why Is ADMA BIOLOGICS INC (ADMA) Stock Up Today?

ADMA Biologics shares surged 26.05% to $13.21, marking a 10-month high. The primary driver was a third-quarter 2026 earnings report that beat expectations, fueled by strong demand for its lead product, Asceniv.

What Happened

The company posted better-than-expected financials for the quarter, with revenue and earnings both coming in higher than anticipated. Management highlighted that demand for Asceniv surged, driving margin expansion. In contrast, the company’s other product, Bivigam, faced pressure, and receivables lagged the target range. The CEO stated that the star drug Asceniv is just getting started. Following the results, ADMA Biologics raised its guidance. Analysts responded positively, with Cantor Fitzgerald raising its price target to $13 from $12 while maintaining a Neutral rating. Canaccord also raised its price target to $19 from $18.

What The Data Shows

The stock printed 27 fresh 52-week highs on November 5, 2026. The 52-week range stands at $7.21 to $20.46. Fundamentals include a market cap of $2.5 billion, a P/E ratio of 15.0, and a net margin of 33.0%. Revenue grew 8.0% on a trailing twelve-month basis. The stock has a beta of 0.66. Over the last eight sessions prior to this move, the stock had declined 5.3% from $11.06 to $10.48. In the last 90 days, there were no insider buys and one sell totaling $1.8 million, with the most recent sale by President and CEO Adam S. Grossman on November 5, 2026. Congressional disclosures show one buy and one sell in the last 90 days, with the most recent filing on September 22, 2026.

What To Watch

Investors will monitor how the raised guidance plays out in upcoming quarters, particularly regarding the continued surge in Asceniv demand and the performance of Bivigam.